# UnitedHealthcare and PacifiCare Commercial

## ASMANEX® and FORADIL® Now Tier 1 (lowest co-pay amount) at PacifiCare Effective January 1, 2008

### Formulary Status at UnitedHealthcare and PacifiCare

| | |
|---|---|
| **ASMANEX®** | **Tier 1** |
| **FORADIL®** | **Tier 1** |
| Pulmicort Turbuhaler® | Tier 1 |
| QVAR® | Tier 1 |
| Advair Diskus® | Tier 3 |
| Azmacort® | Tier 3 |
| Flovent® | Tier 3 |
| Serevent® Diskus® | Tier 3 |

Asmanex® Twisthaler® 220 mcg
(mometasone furoate inhalation powder)

Foradil® Aerolizer®
(formoterol fumarate inhalation powder) 12 mcg

Please see accompanying full Prescribing Information.

Please see indication and important safety information on the back.

**Tier 1** is the lowest co-payment option. For the lowest out-of-pocket expense, you should prescribe Tier 1 medications for appropriate patients. (adapted from http://www.pdlinfo.com)



**Please see accompanying full Prescribing Information.**
**This information is subject to change.**


Printed in the USA FST5900 01/08

Schering-Plough

For patients 12 years and older whose asthma can be managed with ICS plus occasional use of rescue medication,

# ASMANEX® Before Combination*

## Consider all the reasons to choose ASMANEX®:

- **8 out of 10 persistent asthma patients have moderate or mild disease**[1]
  - — According to a survey of 333 physicians who treat asthma patients 12 years and older
- **ICSs are the preferred foundation therapy for moderate and mild** persistent asthma[2]
- In a study of mostly **moderate asthma patients previously maintained on BID ICS therapy, ASMANEX® demonstrated superior** $FEV_1$ improvement vs Pulmicort†[3]
- **The only ICS approved for once-daily dosing‡** at initiation and maintenance treatment of asthma[4]
  - — For patients previously treated with bronchodilators alone or ICSs
- **Excellent managed care access**[5]

**Once-Daily Evening Dosing**[4]
Patients previously maintained on bronchodilators and/or ICS

RECOMMENDED STARTING DOSE
1 inhalation in the evening (220 mcg)

HIGHEST RECOMMENDED DOSE
2 inhalations in the evening† (440 mcg)
**OR**
may be administered as one inhalation twice daily (440 mcg)




**Indications**

ASMANEX®TWISTHALER® is for the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older.

ASMANEX®TWISTHALER® is also indicated for asthma patients who require oral corticosteroid therapy, where adding ASMANEX®TWISTHALER® therapy may reduce or eliminate the need for oral corticosteroids.

ASMANEX®TWISTHALER® is NOT indicated for the relief of acute bronchospasm.

**Important safety information**

ASMANEX®TWISTHALER® is contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required.

The most common adverse events with ASMANEX®TWISTHALER® (vs placebo) reported in clinical trials involving patients previously maintained on inhaled corticosteroids and/or bronchodilators were: headache, 17% to 22% (vs 20%); allergic rhinitis, 11% to 15% (vs 13%); pharyngitis, 8% to 13% (vs 7%); and upper respiratory infection, 8% to 15% (vs 7%).The most common adverse events versus placebo for patients previously maintained on oral corticosteroids were (ASMANEX® vs placebo): musculoskeletal pain (22% vs 14%), oral candidiasis (22% vs 9%), allergic rhinitis (20% vs 5%), arthralgia (13% vs 7%), fatigue (13% vs 2%), depression (11% vs 0%), and sinus congestion (9% vs 0%).

CAUTION: Adrenal insufficiency may occur when transferring patients from systemic steroids (see WARNINGS in full Prescribing Information).

Please see accompanying full Prescribing Information.

*Combination of ICS + LABA therapy.

†An 8-week, multicenter, placebo-controlled, double-blind, double-dummy study of 262 patients with mostly moderate persistent asthma. Previous ICS therapies were discontinued at baseline; patients were then randomized to AM treatment with ASMANEX®, Pulmicort®, or placebo.[3]

‡The 440 mcg daily dose may be administered as 2 inhalations once daily or 1 inhalation twice daily. Patients previously treated with oral corticosteroids will require BID dosing.

**References: 1.** NOP World Health. The Treatment of Asthma Study XXII. Analytical Report August 2004. **2.** *Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma: Update on Selected Topics 2002.* Bethesda, Md: National Heart, Lung, and Blood Institute, National Institutes of Health, US Dept. of Health and Human Services; June 2003. NIH publication 02-5074. **3.** Corren J, Berkowitz R, Murray JJ, Prenner B. Comparison of once-daily mometasone furoate versus once-daily budesonide in patients with moderate persistent asthma. *Int J Clin Pract.* 2003;57:567-572. **4.** ASMANEX® Prescribing Information. Schering Corporation. **5.** Data on file. Schering Corporation.

Schering-Plough



Asmanex® Twisthaler® 220 mcg
(mometasone furoate inhalation powder)

FORADIL® AEROLIZER® (formoterol fumarate inhalation powder) 12 mcg is indicated for long-term, twice-daily (morning and evening) administration in the maintenance treatment of asthma and in the prevention of bronchospasm in adults and children 5 years of age and older with reversible obstructive airways disease, including patients with symptoms of nocturnal asthma.

Long-acting $\beta_2$-adrenergic agonists may increase the risk of asthma-related death (see WARNINGS section of Prescribing Information). Therefore, when treating patients with asthma, FORADIL® AEROLIZER® should only be used as additional therapy for patients not adequately controlled on other asthma-controller medications (eg, low- to medium-dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with two maintenance therapies, including FORADIL® AEROLIZER®. It is not indicated for patients whose asthma can be managed by occasional use of inhaled, short-acting $\beta_2$-agonists or for patients whose asthma can be successfully managed by inhaled corticosteroids or other controller medications along with occasional use of inhaled, short-acting $\beta_2$-agonists.

FORADIL® AEROLIZER® is also indicated for the acute prevention of exercise-induced bronchospasm (EIB) in adults and children 5 years of age and older, when administered on an occasional, as-needed basis. FORADIL® capsules should be administered only by the oral inhalation route using only the AEROLIZER® inhaler. The recommended total daily dose of FORADIL® AEROLIZER® should not exceed 24 mcg (1 capsule twice daily).

**Important Safety Information**

**WARNING:** Long-acting $\beta_2$-adrenergic agonists may increase the risk of asthma-related death. Therefore, when treating patients with asthma, FORADIL® AEROLIZER® should only be used as additional therapy for patients not adequately controlled on other asthma-controller medications (eg, low- to medium-dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with two maintenance therapies, including FORADIL® AEROLIZER®. Data from a large placebo-controlled US study that compared the safety of another long-acting $\beta_2$- adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol may apply to formoterol (a long-acting $\beta_2$-adrenergic agonist), the active ingredient in FORADIL® AEROLIZER® (see WARNINGS section of Prescribing Information).

In asthma clinical trials, the most common adverse events for FORADIL® AEROLIZER® and placebo groups were viral infection, bronchitis, and chest infection. Other adverse events greater than or equal to 1% for FORADIL® AEROLIZER® and placebo, respectively, included dyspnea (2.1% vs 1.7%), chest pain (1.9% vs 1.3%), tremor (1.9% vs 0.4%), dizziness (1.6% vs 1.5%), insomnia (1.5% vs 0.8%), tonsillitis (1.2% vs 0.7%), rash (1.1% vs 0.7%), and dysphonia (1.0% vs 0.9%).

Adverse reactions with FORADIL® AEROLIZER® are similar to other selective $\beta_2$-agonists; eg, angina, hypertension or hypotension, tachycardia, arrhythmias, nervousness, headache, tremor, dry mouth, palpitation, muscle cramps, nausea, dizziness, fatigue, malaise, hypokalemia, hyperglycemia, metabolic acidosis and insomnia. FORADIL® AEROLIZER® should not be used to treat acute symptoms or used more than twice daily. Acute symptoms should be treated with inhaled, short-acting selective $\beta_2$-agonists. FORADIL® AEROLIZER® should be used with caution in patients with cardiovascular disorders. FORADIL® AEROLIZER® is not a substitute for inhaled or oral corticosteroids and, in the treatment of asthma, they should not be stopped or reduced at the time FORADIL® AEROLIZER® is initiated.

ASMANEX® TWISTHALER® 220 mcg (mometasone furoate inhalation powder) is indicated for the maintenance treatment of asthma as prophylactic therapy in patients 12 years of age and older. ASMANEX® TWISTHALER® is also indicated for asthma patients who require oral corticosteroid therapy, where adding ASMANEX® TWISTHALER® therapy may reduce or eliminate the need for oral corticosteroids.

ASMANEX® TWISTHALER® is NOT indicated for the relief of acute bronchospasm.

**Important Safety Information**

ASMANEX® TWISTHALER® is contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required.

The most common adverse events with ASMANEX® TWISTHALER® (vs placebo) reported in clinical trials involving patients previously maintained on inhaled corticosteroids and/or bronchodilators were: headache, 17% to 22% (vs 20%); allergic rhinitis, 11% to 15% (vs 13%); pharyngitis, 8% to 13% (vs 7%); and upper respiratory infection, 8% to 15% (vs 7%).

The most common adverse events versus placebo for patients previously maintained on oral corticosteroids were (ASMANEX® vs placebo): musculoskeletal pain (22% vs 14%), oral candidiasis (22% vs 9%), allergic rhinitis (20% vs 5%), arthralgia (13% vs 7%), fatigue (13% vs 2%), depression (11% vs 0%), and sinus congestion (9% vs 0%).

CAUTION: Adrenal insufficiency may occur when transferring patients from systemic steroids (see WARNINGS in full Prescribing Information).

**Please see accompanying full Prescribing Information for FORADIL® AEROLIZER® and ASMANEX® TWISTHALER®.**